NasdaqGS - Nasdaq Real Time Price USD

Regeneron Pharmaceuticals, Inc. (REGN)

925.28 +106.51 (+13.01%)

As of 3:37:23 PM EDT. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Regeneron Reports Third Quarter 2026 Financial and Operating Results

GlobeNewswire 9h ago

REGN
+13.01%
SNY
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

GlobeNewswire 4d ago

REGN
+13.01%
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

GlobeNewswire 24d ago

REGN
+13.01%
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire 29d ago

REGN
+13.01%
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

GlobeNewswire 29d ago

REGN
+13.01%
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

GlobeNewswire 29d ago

REGN
+13.01%
SNY
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

GlobeNewswire 1mo ago

REGN
+13.01%
Veeva Vault CRM Selected by Regeneron

PR Newswire 2mo ago

REGN
+13.01%
VEEV
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

GlobeNewswire 2mo ago

REGN
+13.01%
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

GlobeNewswire 29d ago

SNY

REGN
+13.01%
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation

TMX Newsfile 2mo ago

MRK

REGN
+13.01%
ROP.SW
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

GlobeNewswire 1mo ago

AMGN

1801.HK

NVS

Performance Overview

Return	REGN	S&P 500 (^GSPC)
YTD	+20.28%	+10.32%
1-Year	+42.13%	+10.70%
3-Year	+20.04%	+81.25%

U.S. markets close in 16m

Regeneron Pharmaceuticals, Inc. (REGN)

Trading disclosure

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

Veeva Vault CRM Selected by Regeneron

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

Performance Overview